CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A

Area of Science:

• Molecular Oncology
• Cancer Therapeutics

Background:

• Targeting translation initiation is a novel anti-cancer strategy exploiting dysregulated MAPK and PI3K-mTOR pathways in cancer.
• Eukaryotic initiation factor 4F (eIF4F), a complex including eIF4A, regulates translation and ribosome recruitment.

Purpose of the Study:

• To validate rocaglates as anti-cancer agents by linking their efficacy to the inhibition of the eIF4A subunit of eIF4F.
• To explore the utility of genetic complementation and CRISPR/Cas9 editing for drug-target validation.

Main Methods:

• Utilized genetic complementation approaches for ex vivo and in vivo drug-target validation.
• Employed CRISPR/Cas9-mediated gene editing to confirm the mechanism of action of rocaglates.

Main Results:

• Rocaglates were shown to deplete the eIF4A helicase subunit from the eIF4F complex.
• Rocaglates demonstrated anti-tumor activity as single agents in preclinical xenograft models.
• The anti-cancer effects of rocaglates were directly linked to their inhibition of eIF4A.

Conclusions:

• Genetic validation confirms that rocaglates' anti-tumor properties are mediated by eIF4A inhibition.
• Rocaglates represent a promising therapeutic strategy, potentially reversing resistance to existing targeted therapies.